At the heart of Smilow Cancer Hospital and Yale Cancer Center, our commitment to safety, compassionate care, and research excellence will always remain.
Patient and Cancer Information
Yale Cancer Center is Connecticut's only cancer center designated as a Comprehensive Cancer Center by the National Cancer Institute- and one of only 57 in the nation. The significance of this designation has profound implications for those who choose Smilow Cancer Hospital as the place where they will be cared for and receive treatment for their cancer. National Cancer Institute cancer centers are national leaders in cancer research, prevention, detection, and treatment. This provides patients at Smilow Cancer Hospital with novel treatment options and expert care.
The delivery of cancer care is becoming ever more complex, involving multiple disciplines for the diagnosis and treatment of patients. In response, Smilow Cancer Hospital and Yale Cancer Center have developed 13 multidisciplinary clinical centers to care for patients diagnosed with cancer. The clinical centers allow physicians and specialists at Smilow Cancer Hospital to focus their expertise on specific types of cancers enabling them to provide superior care to our patients through a patient-friendly system of care led by a nurse coordinator. Our nationally recognized physicians provide unparalleled cancer expertise and are leaders in both the treatment of cancers and the development of innovative treatment strategies.
The key characteristics of the 13 Clinical Centers at Smilow Cancer Hospital are:
- Patient centered care
- Rapid access to appointments and relevant tests
- Personalized care led by a physician in collaboration with a team of specialists
- Personal communication and assistance from a dedicated intake specialist and nurse coordinator
- Compassion and support for the psychological aspects of cancer
- Rapid communication with and involvement of outside primary care and referring physicians
Ways to stay safe during chemotherapy and immunotherapy.
Latest News
- June 27, 2024Source: Oncology Nursing News
Luspatercept Improves Response Rates, Transfusion Independence for Lower-Risk MDS
- June 26, 2024
Yale Study Finds Potential in Predicting Immunotherapy Outcomes in Patients with Melanoma
- June 26, 2024Source: OncLive
Dr. Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer
- June 25, 2024Source: Yale News
Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy
- June 25, 2024Source: Medscape
Neurofilament Light Chain Detects Early Chemotherapy-Related Neurotoxicity
- June 25, 2024Source: CURE
Imdelltra for Small Cell Lung Cancer Addresses Key Unmet Needs
- June 25, 2024Source: Best Life
Colon Cancer Patients Share Easy-to-Miss Bathroom Symptoms
- June 24, 2024
Foundation Created by Joseph Madri, MD/PhD, Professor Emeritus of Pathology, Supports Many Causes
- June 24, 2024Source: HealthDay
Timing of Chemo Could Be Key to Pancreatic Cancer Outcomes
- June 24, 2024Source: New York Post
I’m a doctor — beware this one unusual, ‘highly concerning’ colon cancer sign
- June 24, 2024Source: CAP Today
How Rapid Autopsies Bridge Clinical Care and Research
- June 23, 2024Source: HuffPost
The 1 Unexpected Sign Of Colon Cancer, According To Doctors